DCM vs. HCM: How These Heart Conditions Differ and How to Manage Them

Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are two distinct heart conditions that alter the structure and function of the heart. While they share some symptoms, their effects on the heart differ significantly. Both can be serious if untreated, but medical advances now offer ways to manage them effectively.

DCM weakens and thins the wall of the left ventricle, causing the heart to enlarge and pump less efficiently. Over time, this can lead to reduced blood flow and heart failure. In contrast, HCM thickens the heart muscle, forcing it to work harder and sometimes obstructing blood flow.

Both conditions can cause similar symptoms, including shortness of breath, fatigue, chest pain, and swelling—especially during physical activity. Without treatment, they may result in heart failure or dangerous irregular heartbeats. However, medications and lifestyle adjustments can help control these risks.

DCM is treated with drugs like ACE inhibitors, beta-blockers, and SGLT2 inhibitors, alongside devices such as pacemakers or, in severe cases, heart transplants. HCM management often involves beta-blockers, calcium channel blockers, and newer medications like cardiac myosin inhibitors. Some patients may also need implantable cardioverter-defibrillators (ICDs) to regulate heart rhythms.

Genetics play a role in both conditions, though differently. Around one in six DCM cases has a known genetic link, while HCM is more frequently inherited. Research in precision medicine continues to improve diagnosis and treatment options for both.

With the right medical care, people with DCM or HCM can slow disease progression and maintain a good quality of life. Medications, devices, and lifestyle changes help manage symptoms and reduce complications. Early diagnosis and tailored treatment remain key to long-term well-being.